Sanofi plans 5 billion euro buyback, sees higher profit growth
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as ...
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as ...
China is seeking to strengthen economic ties with individual members of the European UnionSanofi plans to invest around US$1.05 billion ...
Modulus can also be reconfigured within a few days to transform between technological platforms, a process which traditionally takes months ...
Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling ...
Doliprane is France’s best-selling drug and news that it could be partially sold to a foreign investor has prompted political ...
BANKS and other lenders are lining up more than 10 billion euros (S$14.3 billion) of debt to back a buyout ...
Sanofi will invest more than 1 billion euros (S$1.45 billion) at three facilities in France as it ramps up production ...
Sanofi and Novavax signed a licensing agreement that includes commercialising a combined Covid-19 and flu shot. Novavax will receive US$500 million ...
SANOFI reported on Thursday (Apr 25) that its first-quarter operating income declined 14.7 per cent, as unfavourable currency effects and ...
SANOFI has reached an agreement in principle to settle 4,000 US lawsuits linking the discontinued heartburn drug Zantac to cancer, ...
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2024 Forbes 40under40. All Rights Reserved.